Results 21 to 30 of about 3,887,212 (164)

Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis

Endocrinology, Diabetes & Metabolism Case Reports, 2022
Von Hippel–Lindau’s disease (VHL) is a hereditary tumor syndrome characterized by its prototype lesions, hemangioblastomas, and renal cell carcinomas. Treatment for renal cell carcinomas can ultimately result in long-term dialysis.
N Ayub, A J A T Braat, H J L M Timmers, M G E H Lam, R S van Leeuwaarde   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

, 2021
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and
Van Cutsem, Eric, Jeroen Dekervel, Dekervel, Jeroen, Eric Van Cutsem, Kristof Baete, Deroose, Christophe M., Baete, Kristof, Kristiaan Nackaerts, Paul Clement, Niloefar Ahmadi Bidakhvidi, Verslype, Chris, Christophe M. Deroose, Clement, Paul, Ahmadi Bidakhvidi, Niloefar, Karolien Goffin, Chris Verslype, Goffin, Karolien, Nackaerts, Kristiaan   +17 more
core   +1 more source

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy [PDF]

, 2021
Purpose of Review: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (
Minczeles, N. S., Hofland, J., Brabander, T., de Herder, W. W.   +3 more
core   +2 more sources

Effect of Peptide Receptor Radionuclide Therapy in Combination with Temozolomide against Tumor Angiogenesis in a Glioblastoma Model

, 2021
Cell adhesion receptor integrin αvβ3 is a promising biomarker for developing tumor-angiogenesis targeted theranostics. In this study, we aimed to examine the therapeutic potential of peptide receptor radionuclide therapy (PRRT) with 188Re-IDA-D-[c(RGDfK)]
In Ho Song, Nunzio Denora, Hyun Soo Park, Byung Chul Lee, Sang Eun Kim, Ji Young Choi, Sang Hee Lee, Jae Ho Jung, Francesco Leonetti   +8 more
core   +1 more source

Combination of [¹⁷⁷Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model

Pharmaceutics, 2022
Peptide receptor radionuclide therapy (PRRT) relies on α- and β-emitting radionuclides bound to a peptide that commonly targets somatostatin receptors (SSTRs) for the localized killing of tumors through ionizing radiation.
Marina Simón, Jesper Tranekjær Jørgensen, Harshvardhan A. Khare, Camilla Christensen, Carsten Haagen Nielsen, Andreas Kjaer   +5 more
doaj   +1 more source

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Diagnostics, 2013
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via ...
Michael Bzorek, Michael Holmsgaard Kristensen, Andreas Kjaer, Andreas Klaus Pfeifer, Ulrich Knigge, Yin Wu, Rajendra Singh Garbyal, Palle Rasmussen, Rebecca Myschetzky   +8 more
doaj   +1 more source

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study

European Journal of Hybrid Imaging, 2021
Background Early [68Ga]Ga-DOTA-TOC PET/CT imaging after peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasm patients is often used as a prognosticator for survival, but lacks validity.
Sander C. Ebbers, Muriël Heimgartner, Maarten W. Barentsz, Rachel S. van Leeuwaarde, Mark J. C. van Treijen, Marnix M. E. G. Lam, Arthur J. A. T. Braat   +6 more
doaj   +1 more source

The effects of peptide receptor radionuclide therapy on the neoplastic and normal pituitary [PDF]

, 2023
Pituitary neuroendocrine tumours (PitNETs) are usually benign and slow-growing; how- ever, in some cases, they may behave aggressively and become resistant to conventional treatments.
Pedro Marques, Marques, Pedro
core   +1 more source

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors

Frontiers in Oncology, 2021
IntroductionNeuroendocrine neoplasms including neuroendocrine tumors (NETs) are often diagnosed as primary disseminated or inoperable. In those cases, systemic extensive therapy is necessary, but radical treatment is unlikely.
Marta Opalińska, Anna Sowa-Staszczak, Anna Grochowska, Helena Olearska, Alicja Hubalewska-Dydejczyk   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. [PDF]

, 2020
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting ...
Steinmann-Schwager, Stephanie, Häfliger, Simon, Schoch, Eric, Wild, Damian, Reichmann, Jan, Pless, Miklos, Seidel, Ann-Katrin   +6 more
core   +2 more sources